AstraZeneca (AZN) said Monday the first patient was dosed in the phase 3 Destiny Endometrial trial testing Enhertu as treatment after surgery for endometrial cancer.
The study is comparing Enhertu with or without radiotherapy versus standard chemotherapy with or without radiotherapy, the company said.
The trial is being conducted with The GOG Foundation and the European Network of Gynecological Oncological Trial Groups, with Gineco as the lead group, it said.
Enhertu was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments